$HRTX @ 13.05 Heron Therapeutics, Inc. (HRTX) Giv
Post# of 22755
(Total Views: 55)
Posted On: 01/09/2017 9:07:41 AM
$HRTX @ 13.05
Heron Therapeutics, Inc. (HRTX) Given a $29.00 Price Target by Jefferies Group Analysts
Posted by Don Majors on Jan 9th, 2017 // No Comments
Heron Therapeutics logoHeron Therapeutics, Inc. (NASDAQ:HRTX) has been assigned a $29.00 price target by stock analysts at Jefferies Group in a research note issued on Thursday. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Jefferies Group’s target price points to a potential upside of 122.22% from the stock’s previous close.
Other equities analysts have also recently issued research reports about the company. Leerink Swann restated a “buy” rating and set a $33.00 price objective on shares of Heron Therapeutics in a report on Sunday, October 2nd. Cowen and Company restated a “buy” rating and set a $40.00 price objective on shares of Heron Therapeutics in a report on Sunday, December 11th. Zacks Investment Research upgraded Heron Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, November 23rd. Cantor Fitzgerald restated a “buy” rating and set a $34.00 price objective on shares of Heron Therapeutics in a report on Thursday, November 10th. Finally, JMP Securities restated a “buy” rating on shares of Heron Therapeutics in a report on Wednesday, November 9th. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $37.75.
Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)
Shares of Heron Therapeutics (NASDAQ:HRTX) opened at 13.05 on Thursday. The stock has a 50 day moving average price of $14.54 and a 200-day moving average price of $17.06. Heron Therapeutics has a 1-year low of $12.30 and a 1-year high of $25.84.
Heron Therapeutics (NASDAQ:$HRTX) last posted its quarterly earnings data on Tuesday, November 8th. The biotechnology company reported ($1.24) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.17) by $0.07. On average, equities analysts anticipate that Heron Therapeutics will post ($4.50) EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in HRTX. Franklin Resources Inc. raised its position in Heron Therapeutics by 3.0% in the second quarter. Franklin Resources Inc. now owns 7,752,460 shares of the biotechnology company’s stock valued at $139,937,000 after buying an additional 229,182 shares during the last quarter. FMR LLC raised its position in Heron Therapeutics by 1.2% in the second quarter. FMR LLC now owns 5,493,420 shares of the biotechnology company’s stock valued at $99,156,000 after buying an additional 63,968 shares during the last quarter. Janus Capital Management LLC raised its position in Heron Therapeutics by 14.8% in the second quarter. Janus Capital Management LLC now owns 4,013,921 shares of the biotechnology company’s stock valued at $72,450,000 after buying an additional 516,166 shares during the last quarter. Baker BROS. Advisors LP bought a new position in Heron Therapeutics during the third quarter valued at approximately $49,230,000. Finally, Vanguard Group Inc. raised its position in Heron Therapeutics by 5.0% in the second quarter. Vanguard Group Inc. now owns 1,215,343 shares of the biotechnology company’s stock valued at $21,937,000 after buying an additional 58,039 shares during the last quarter.
About Heron Therapeutics
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
5 Day Chart for NASDAQ:HRTX
Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
Heron Therapeutics, Inc. (HRTX) Given a $29.00 Price Target by Jefferies Group Analysts
Posted by Don Majors on Jan 9th, 2017 // No Comments
Heron Therapeutics logoHeron Therapeutics, Inc. (NASDAQ:HRTX) has been assigned a $29.00 price target by stock analysts at Jefferies Group in a research note issued on Thursday. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Jefferies Group’s target price points to a potential upside of 122.22% from the stock’s previous close.
Other equities analysts have also recently issued research reports about the company. Leerink Swann restated a “buy” rating and set a $33.00 price objective on shares of Heron Therapeutics in a report on Sunday, October 2nd. Cowen and Company restated a “buy” rating and set a $40.00 price objective on shares of Heron Therapeutics in a report on Sunday, December 11th. Zacks Investment Research upgraded Heron Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, November 23rd. Cantor Fitzgerald restated a “buy” rating and set a $34.00 price objective on shares of Heron Therapeutics in a report on Thursday, November 10th. Finally, JMP Securities restated a “buy” rating on shares of Heron Therapeutics in a report on Wednesday, November 9th. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $37.75.
Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)
Shares of Heron Therapeutics (NASDAQ:HRTX) opened at 13.05 on Thursday. The stock has a 50 day moving average price of $14.54 and a 200-day moving average price of $17.06. Heron Therapeutics has a 1-year low of $12.30 and a 1-year high of $25.84.
Heron Therapeutics (NASDAQ:$HRTX) last posted its quarterly earnings data on Tuesday, November 8th. The biotechnology company reported ($1.24) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.17) by $0.07. On average, equities analysts anticipate that Heron Therapeutics will post ($4.50) EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in HRTX. Franklin Resources Inc. raised its position in Heron Therapeutics by 3.0% in the second quarter. Franklin Resources Inc. now owns 7,752,460 shares of the biotechnology company’s stock valued at $139,937,000 after buying an additional 229,182 shares during the last quarter. FMR LLC raised its position in Heron Therapeutics by 1.2% in the second quarter. FMR LLC now owns 5,493,420 shares of the biotechnology company’s stock valued at $99,156,000 after buying an additional 63,968 shares during the last quarter. Janus Capital Management LLC raised its position in Heron Therapeutics by 14.8% in the second quarter. Janus Capital Management LLC now owns 4,013,921 shares of the biotechnology company’s stock valued at $72,450,000 after buying an additional 516,166 shares during the last quarter. Baker BROS. Advisors LP bought a new position in Heron Therapeutics during the third quarter valued at approximately $49,230,000. Finally, Vanguard Group Inc. raised its position in Heron Therapeutics by 5.0% in the second quarter. Vanguard Group Inc. now owns 1,215,343 shares of the biotechnology company’s stock valued at $21,937,000 after buying an additional 58,039 shares during the last quarter.
About Heron Therapeutics
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
5 Day Chart for NASDAQ:HRTX
Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
(0)
(0)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
Scroll down for more posts ▼